ANKTIVA®
Clinical Trials
Find a Trial
Become a Trial
Investigator
License our Cells
Science
Platforms
Pipeline
Expanded Access
Research
Approach
Patients
Trial Investigators
Researchers
Condition
Bladder Cancer
Glioblastoma
HIV
Lynch / Colon Cancer
Non-Hodgkin Lymphoma
Human Papillomavirus
Non-Small Cell Lung Cancer
Company
About Us
Investors
News and Events
Contact
Careers
Founder’s Vision
Cancer Moonshot 2020
Childhood Cancer – Sen. McCain
Cancer Moonshot Announcement
Formation of ImmunityBio
Select Page
Acceptance Requirements
Adult patients diagnosed with CD19 and CD20-positive B-cell non-Hodgkin lymphoma
Have completed two lines of chemotherapy
Search for:
Recent Posts
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency
ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom
ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® is Now Effective
